Showing 1179 results
- https://www.novartis.com/news/media-releases/novartis-accelerates-cancer-immunotherapy-efforts-aduro-biotech-alliance-and-launch-new-immuno-oncology-research-groupCollaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances…
- https://www.novartis.com/news/media-releases/novartis-cosentyxtm-two-year-data-shows-sustained-effect-and-favorable-safety-profile-psoriasis-patientsAfter two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who…
- https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-medicines-strategy-and-renal-pipeline-agreement-acquire-chinook-therapeutics-usd-32bn-upfront-usd-40-shareAd hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare…
- https://www.novartis.com/news/media-releases/sandoz-introduces-act4biosimilars-action-plan-accelerate-patient-access-biosimilar-medicinesDespite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic…
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
https://www.novartis.com/news/media-releases/novartis-signs-agreement-divest-front-eye-ophthalmology-assets-line-focused-strategyDivested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of…- https://www.novartis.com/news/media-releases/novartis-publishes-new-five-year-efficacy-data-kesimpta-ofatumumab-treatment-relapsing-multiple-sclerosisContinuous Kesimpta® (ofatumumab) treatment maintained profound suppression of MRI lesion activity and resulted in an increase in the number of patients with relapsing forms of multiple sclerosis (…
- https://www.novartis.com/news/media-releases/sandoz-launch-hyrimoz-adalimumab-adaz-high-concentration-formulation-marking-sandoz-entrance-us-immunology-spaceHyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab HCF biosimilars…
- https://www.novartis.com/news/media-releases/novartis-will-appeal-us-court-appeals-uphold-validity-entresto-combination-patent-maintains-2023-guidance-and-mid-term-outlookAd hoc announcement pursuant to Art. 53 LR U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis will appeal…
- https://www.novartis.com/news/media-releases/novartis-builds-neuroscience-pipeline-and-xrna-platform-capabilities-acquisition-dtx-pharmaDTx Pharma is a preclinical stage biotechnology company that focuses on developing siRNA therapies for neuroscience indications, leveraging its proprietary fatty acid ligand-conjugated…
- https://www.novartis.com/news/media-releases/novartis-delivers-strong-sales-growth-robust-margin-expansion-and-raises-guidance-announces-usd-15-billion-share-buyback-and-board-endorses-sandoz-spin-off12Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 118
- › Next page